SCHEDULE: FMR LLC Reports Stake in Wave Life Sciences

FMR LLC and Abigail P. Johnson have filed a Schedule 13G, reporting beneficial ownership of 5,192,761.43 shares of Wave Life Sciences common stock, representing 2.8% of the class.

Summary

• FMR LLC and Abigail P. Johnson have jointly filed an amended Schedule 13G, indicating their beneficial ownership of Wave Life Sciences Ltd. common stock.
• As of March 31, 2026, the total number of shares beneficially owned is 5,192,761.43, which constitutes 2.8% of the total class of securities.
• FMR LLC, organized in Delaware, is classified as a holding company (HC).
• Abigail P. Johnson, a U.S. citizen, is classified as an insider (IN).
• The filing indicates that FMR LLC has sole voting power over 5,189,539.00 shares and sole dispositive power over 5,192,761.43 shares.
• Abigail P. Johnson has sole dispositive power over 5,192,761.43 shares.
• No single other person is known to have an interest exceeding five percent of the total outstanding common stock.
• The filing is made pursuant to Rule 13d-1(b) and includes a Rule 13d-1(k)(1) agreement for joint filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of beneficial ownership by a large investment firm and does not contain new strategic information or performance data about Wave Life Sciences itself.

Positives

• FMR LLC and Abigail P. Johnson maintain a significant, though not controlling, stake in Wave Life Sciences, suggesting continued confidence or investment interest.
• The filing is an amendment, indicating ongoing monitoring and reporting of ownership, which is standard practice for institutional investors.

Negatives

• The ownership stake of 2.8% is below the 5% threshold that typically triggers more detailed disclosure requirements for significant beneficial ownership.
• The filing does not provide any specific strategic insights or commentary from FMR LLC or Abigail P. Johnson regarding their investment thesis or future intentions.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company itself.
• Potential future changes in ownership by FMR LLC or Abigail P. Johnson could impact the stock price, though no such intentions are stated.

Future Outlook

The filing does not contain any forward-looking statements or guidance from FMR LLC or Abigail P. Johnson regarding Wave Life Sciences.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors and investment management firms like FMR LLC when their ownership stake in a public company crosses certain reporting thresholds. This filing indicates FMR LLC's ongoing management of its investment portfolio, specifically its holdings in the biotechnology or life sciences sector where Wave Life Sciences operates.

Stakeholder Impact

• Shareholders: The filing confirms the continued interest of a significant institutional investor, which can be viewed positively, but the 2.8% stake is unlikely to cause immediate significant price movement.
• Management of Wave Life Sciences: The filing provides transparency regarding ownership, which is a standard requirement and does not directly impact management operations.
• Other Investors: Provides transparency on the ownership structure, allowing other investors to understand the landscape of major holders.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to monitor their beneficial ownership of Wave Life Sciences' common stock and file amendments to Schedule 13G as required by SEC regulations.

Key Dates

Keywords

Schedule 13G, FMR LLC, Abigail P. Johnson, Wave Life Sciences, Beneficial Ownership, Common Stock, SEC Filing, Investment, Holding Company, Insider